Quantcast

Latest H5N1 clinical trials Stories

2011-09-09 13:32:33

Vaccine is first of its kind to earn FDA approval to test in humans For the first time, a malaria vaccine that uses the entire malaria parasite has proven safe and shown promise to produce a strong immune response in a clinical trial, according to a new study co-authored by researchers at the University of Maryland School of Medicine Center for Vaccine Development. The vaccine is unique in that it employs the entire malaria parasite, while most experimental malaria vaccines consist of just...

2011-09-08 20:52:53

Using live but weakened malaria parasites as the basis of a vaccine represents a potentially encouraging anti-malaria strategy, according to results of follow-up animal studies performed after the conclusion of a recent clinical trial in humans. The research was conducted by scientists at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, working in concert with a large team of collaborators. The findings...

2011-08-23 18:02:09

New research from the Trudeau Institute may help to explain why live attenuated influenza vaccine (LAIV), commonly known as FluMist, elicits protection. The research is published in this month's issue of Vaccine. The journal article is entitled "Live attenuated influenza vaccine (LAIV) impacts innate and adaptive immune responses" and was authored by Trudeau Institute scientist Dr. Laura Haynes and her colleagues. "Our research specifically examines how the vaccine, which is commonly known...

2011-08-16 06:30:00

ATLANTA, Aug. 16, 2011 /PRNewswire/ -- GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), an Atlanta-based, biopharmaceutical firm developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV) infections, today announced receipt of a $3.6 million annual notice of award for the Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) Grant supporting GeoVax's HIV/AIDS vaccine program. This grant was originally awarded in 2007 to GeoVax by the National Institutes of...

2011-08-15 09:00:00

SAN DIEGO, Aug. 15, 2011 /PRNewswire/ -- NexBio announced top line data from a Phase 2 clinical trial of DAS181, an investigational drug for treatment and prophylaxis of Influenza-Like Illness (ILI) caused by all types and strains of influenza and parainfluenza viruses, including pandemic influenza strains. In a double-blind, placebo-controlled, Phase 2 trial of otherwise healthy adults infected with influenza virus, treatment with DAS181 resulted in a significant reduction in patients'...


Word of the Day
cruet
  • A vial or small glass bottle, especially one for holding vinegar, oil, etc.; a caster for liquids.
This word is Middle English in origin, and ultimately comes from the Old French, diminutive of 'crue,' flask.
Related